[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-quality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-quality":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,85,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100618517","prospective-clinical-investigation-to-evaluate-the-safety-and-effectiveness-of-juline-in-improving-gluteal-skin-laxity-in-adults-100618517",false,"NCT07332650","Prospective Clinical Investigation to Evaluate the Safety and Effectiveness of Juläine™ in Improving Gluteal Skin Laxity in Adults.","A Pivotal, Open-Label, Two-Arm, Randomized, Parallel-Group, Prospective Clinical Investigation to Evaluate the Safety and Effectiveness of Juläine™ in Improving Gluteal Skin Laxity in Adults.","Inclusion Criteria:\n\n* Adults aged 18 to 55 years;\n* Body Mass Index (BMI) between 18.5 and 24.95 kg\u002Fm².\n* Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin.\n* Women of childbearing potential must be willing to abide by the contraceptive requirements\n* Ability to understand the study and provide informed consent, attend follow-up visits, and follow post-injection instructions.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding, or planned pregnancy\u002Flack of adequate contraception (through 8 weeks post-study);\n* Is planning to donate\u002Fbank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation.\n* Active infection, inflammation or lesions at or near the treatment site.\n* Acute infection at screening;\n* History of autoimmune disease;\n* Immune deficiencies;\n* History of hypertrophic scarring or keloid formation;\n* Previous surgical procedures involving the buttocks\n* Aesthetic procedure on the buttocks (including fillers, elevation wires, radiofrequency, ultrasound, cryotherapy, fat injection, neurotoxin, laser or light treatment, or chemical peel) within 6 months prior to randomization.\n* Hemorrhagic disease or ongoing use of antiplatelets\u002Fanticoagulant therapy.\n* Treatment with chemotherapy, immunosuppressive agents, systemic corticosteroids within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed).\n* Use of hormonal replacement therapy (HRT) unless the participant has been on a stable dose for at least 3 months prior to screening and does not plan to make any changes to the HRT regimen during the study period.\n* Use of topical corticosteroids, topical prescription retinoids in the treatment area within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the baseline visit, or plan to receive such treatment.\n* Use of other agents that inhibit collagen production.\n* Known allergy or hypersensitivity to any component of the investigational product.\n* History of herpes simplex rashes, malignant skin diseases, or any other serious dermatologic or systemic disease.\n* Presence of any condition that may impair wound healing (e.g., connective tissue disorders, severe malnutrition).\n* Planned or ongoing cosmetic procedures involving the buttocks or surrounding area during the period of clinical investigation.\n* Extensive tattoos covering \\>50% of the total gluteal area.\n* Participants actively taking GLP-1 medications with the intention of achieving additional weight loss (expected \\>10% during study) will be excluded. Participants on a stable GLP-1 regimen (≥3 months) for diabetes management or weight maintenance, with documented weight stability (±10% in past 6 months) and no planned or expected weight change \\>10%, may be included.\n* Any other medical or psychological condition that, in the opinion of the investigator, may interfere with participation in clinical research or evaluation of results.","ALL","18 Years","55 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) injections for the treatment of buttock skin laxity.\n\nParticipants will be randomized to an immediate-treatment group or a delayed-treatment group. The immediate-treatment group will receive 2 to 3 treatment sessions over up to 2 months and will be compared with the delayed-treatment group during the control period; the delayed-treatment group will receive the same treatment after the delay.\n\nThe primary objective is to assess clinical improvement in buttock skin elasticity 6 months after the last treatment, defined as an increase in skin elasticity measured by a cutometer. Total study participation is up to 16 months, including follow-up.\n\nThis multicenter trial will be conducted in Brazil.",[27,28],"Skin Quality","Skin Laxity",[30,31,32,33,34,35,36,37],"Poly-L-lactic acid","PLLA","Aesthetic","Injectable filler","Buttocks","Gluteal skin laxity","Buttock skin laxity","Skin elasticity","NOT_YET_RECRUITING","2026-03-16",{"date":41,"type":42},"2026-03-19","ACTUAL",{"date":44,"type":21},"2026-10",{"date":46,"type":21},"2027-06",{"name":48,"class":49},"Nordberg Medical AB","INDUSTRY",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100628846","phase-3-objective-evaluation-of-intradermal-msc-derived-exosome-therapy-on-facial-skin-quality-100628846","NCT07466953","Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality","Objective Analysis of the Effects of Intradermally Administered Mesenchymal Stem Cell-Derived Suspended Exosome Therapy on Facial Skin Quality Using a Standardized Imaging System","Inclusion Criteria:\n\n* • Adults aged 18 to 65 years\n\n  * Individuals presenting facial skin aging signs\n  * Willingness to undergo three intradermal treatment sessions\n  * Ability to comply with study visits and follow-up assessments\n  * Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n\n  * Active skin infection, inflammatory skin disease, or open wounds in the treatment area\n  * History of allergic reactions to injectable dermatologic treatments\n  * Use of systemic or topical retinoids within the past 6 months\n  * Receipt of facial cosmetic procedures (laser treatment, fillers, botulinum toxin, PRP, or similar treatments) within the past 6 months\n  * Presence of autoimmune disease or immunosuppressive conditions\n  * Active malignancy or ongoing cancer treatment\n  * Participation in another clinical study within the past 3 months",true,"65 Years",{"count":60,"type":21},30,[62],"PHASE3","This study aims to evaluate the potential effects of mesenchymal stem cell-derived suspended exosome therapy on facial skin quality using objective imaging analysis. Thirty adult participants will receive intradermal exosome applications in three treatment sessions performed at one-month intervals. Facial skin analysis will be conducted using the VISIA imaging system before each treatment session and six months after the final treatment. The study will examine changes in multiple facial skin characteristics including wrinkles, pigmentation, skin texture, pores, UV spots, red areas, brown spots, and porphyrins to determine whether exosome therapy may improve overall facial skin quality.",[65,66,27],"Skin Aging","Facial Aging",[68,69,70,71,72,73,74],"Exosome Therapy","Mesenchymal Stem Cell Exosomes","Facial Rejuvenation","Skin Imaging","VISIA Skin Analysis","Skin Aging Treatment","Regenerative Dermatology","2026-03-08",{"date":77,"type":42},"2026-03-12",{"date":79,"type":21},"2026-04-01",{"date":81,"type":21},"2026-12-31",{"name":83,"class":84},"Mert Ersan","OTHER",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":57,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100627263","a-study-to-evaluate-the-efficacy-of-collagen-16-serum-alone-against-and-as-an-adjunct-to-radiesse-biostimulation-procedure-in-female-trial-participants-with-aged-skin-100627263","NCT07446361","A Study to Evaluate the Efficacy of Collagen 16 Serum Alone, Against and as an Adjunct to Radiesse® Biostimulation Procedure in Female Trial Participants With Aged Skin","A Randomized Clinical Study to Evaluate the Efficacy of Collagen 16 Serum Alone, Against and as an Adjunct to Radiesse® Biostimulation Procedure in Female Trial Participants With Aged Skin","Inclusion Criteria:\n\n* Female trial participants aged from 30 to 70 years.\n* Trial participants who are regular users of anti-aging cosmetic products.\n* Trial participants presenting with:\n* Wrinkle visibility score ≥3 and ≤6 on a 10-point visual scale.\n* Fine lines visibility score ≥3 and ≤6 on a 10-point visual scale.\n* Crow's feet wrinkle score ≥2 and ≤4 on the L'Oréal Atlas (volume 1 caucasian type).\n* Skin radiance score ≥3 and ≤6 on a 10-point visual scale.\n* Plumpness score ≥3 and ≤6 on a 10-point visual scale\n\nExclusion Criteria:\n\n* Trial participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.\n* Trial participants who are currently participating in another facial clinical study or who have participated in such a study within 1 month that may interfere with the study outcomes.\n* Trial participants presenting with current flaring or severe inflammatory acne or any active dermatological condition that, in the investigator's opinion, could interfere with study assessments.\n* Trial participants who have undergone ablative laser treatments, microneedling, chemical peels, dermabrasion, non-ablative laser, intense pulsed light (IPL), or injectable procedures within the last 12 months from the day of screening.\n* Trial participants who have undergone biostimulation procedures in the past 6 to 9 months from the day of screening\n* Trial participants with a known allergy to any component of the investigational product(s), comparator product(s), or additional products used in the study.\n* Trial participants presenting with any medical or dermatological condition that, in the investigator's opinion, may compromise trial participant safety or interfere with study conduct or evaluation.\n* Trial participants who are unable or unwilling to comply with the study requirements and instructions.\n* Trial participants who are unable to provide written informed consent.\n* Trial participant with clinically significant history of alcoholism or drug abuse;\n* Trial participant who are employees of MSCR or Sponsor","FEMALE","30 Years","70 Years",{"count":96,"type":21},180,[24],"This study aims at assessing the efficacy of improving skin aging signs of a serum containing collagen 16 combined with a biostimulation device in healthy female subjects aged between 30 and 70 years over a period of 13 weeks.",[100,27],"Wrinkle Appearance",[102,103,104,105,106],"anti-aging","cosmetics","collagen 16","biostimulation","placebo serum","2026-03-02",{"date":109,"type":42},"2026-03-03",{"date":111,"type":21},"2026-03-01",{"date":113,"type":21},"2026-09",{"name":115,"class":49},"Vichy Laboratoires",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100606718","a-study-to-evaluate-the-safety-and-effectiveness-of-kytogen-defend-in-facial-skin-quality-improvement-in-adult-participants-100606718","NCT07179198","A Study to Evaluate the Safety and Effectiveness of Kytogen Defend in Facial Skin Quality Improvement in Adult Participants","A Prospective, Multicenter, Randomized, No-Treatment-Controlled, Assessor-Blinded, Superiority Clinical Investigation to Evaluate the Safety and Effectiveness of Kytogen Defend in Facial Skin Quality Improvement","Inclusion Criteria:\n\n* (1) Subjects ≥18 years (subject to the time of signing the ICF), without any restriction on gender; (2) Skin types ranging from type II to IV according to Fitzpatrick classification; (3) The subject exhibits symptoms of dry skin and dull complexion on face, and has a temporary need to improve the quality of facial skin. After evaluation by the investigator, it is deemed suitable for improvement through the medical device used in this trial;\n\nExclusion Criteria:\n\n* (1) Subjects who have known allergies to Carboxymethyl Chitosan Solutions or any ingredients contained in the product; have known allergies to any local anesthetics (e.g., lidocaine or other amide-type anesthetics) or to an excipient of 5% EMLA cream; are allergic to chlorhexidine (or similar products) or to an excipient found in 0.5% alcohol chlorhexidine; or have a history of severe allergies or any episodes of anaphylactic shock; (2) Subjects having participated in other clinical trials within 1 month prior to enrollment in this trial or being currently participating in other clinical trials; (3) Females who are pregnant, breastfeeding, or planning to become pregnant during the study, or those who have been menopausal for less than 1 year or are in the perimenopausal phase without undergoing hormone therapy; (4) Subjects who have been exposed to strong sunlight or strong ultraviolet rays within 1 month before screening, or who are expected to work outdoors for a long time or need to be exposed to strong sunlight or ultraviolet rays during the study period; (5) Having tattoos, piercings, significant facial hair, scars, deformities, unhealed wounds, active skin diseases or inflammation or infections (e.g., herpes, acne, eczema, dermatitis, psoriasis, herpes zoster, mycosis and papillomas, etc.), abscess, granuloma, active or persistent perinasal infection, cancers or precancerous lesions, malignant tumours or skin swellings with unknown nature, unknown injections, and facial subcutaneous fixations (mesh, thread, gold twisted wire), etc. in the injection and evaluation area that may affect the effectiveness evaluation or increase treatment-related risks; (6) Subjects who are considered not suitable for participating in this clinical trial according to evaluation of investigators.",{"count":124,"type":21},500,[24],"This study was designed to evaluate the efficacy and safety of KIO021, an injectable solution for carboxymethyl chitosan, for temporary improvement of facial skin condition. Designed for forward-looking effectiveness.\n\nTo achieve this, it is planned that 500 subjects with dry skin and dull complexion on the face will be included in the injection.",[27],"2025-09-10",{"date":130,"type":42},"2025-09-17",{"date":132,"type":21},"2025-09-22",{"date":134,"type":21},"2026-11-30",{"name":136,"class":49},"Sinclair Pharmaceuticals Limited"]